Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | TRPC1 | P48995 | 2/20 | 0.55 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.55 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.55 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.55 |
| ▸ | STIM2 | Q9P246 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.49 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147829 | 1.00 | HPGD (0.57) | HPGDKDM4EL3MBTL1POLBALDH1A1 | |
| SCHEMBL24804947 | 0.89 | HPGD (0.64) | HPGDKDM4EL3MBTL1POLBALDH1A1 | |
| SCHEMBL20265383 | 0.87 | HPGD (0.57) | HPGDKDM4EL3MBTL1POLBALDH1A1 | |
| SCHEMBL31094479 | 0.87 | HPGD (0.57) | HPGDKDM4EL3MBTL1POLBALDH1A1 | |
| SCHEMBL21604976 | 0.87 | MAPT (0.56) | HPGDKDM4EL3MBTL1POLBALDH1A1 | |
| SCHEMBL17145123 | 0.85 | HPGD (0.62) | HPGDKDM4EL3MBTL1POLBALDH1A1 | |
| SCHEMBL21605077 | 0.83 | TRPC1 (0.56) | HPGDKDM4EL3MBTL1POLBALDH1A1 | |
| SCHEMBL30147967 | 0.83 | TRPC1 (0.56) | HPGDKDM4EL3MBTL1POLBALDH1A1 | |
| SCHEMBL20265245 | 0.83 | KDM4E (0.51) | HPGDKDM4EL3MBTL1POLBALDH1A1 | |
| SCHEMBL21605113 | 0.83 | HPGD (0.62) | HPGDKDM4EL3MBTL1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| CN-112585128-B | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-22 | — | — | US | disclosed |
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-22 | — | — | US | disclosed |
| CN-112585128-A | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2019243964-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | HPGD 2446/4885KDM4E 3312/4885L3MBTL1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.